Literature DB >> 21798988

Analysis of midwall shortening reveals high prevalence of left ventricular myocardial dysfunction in patients with diabetes mellitus: the DYDA study.

Giovanni Cioffi1, Carlo B Giorda, Marcello Chinali, Andrea Di Lenarda, Pompilio Faggiano, Donata Lucci, Aldo P Maggioni, Serge Masson, Gian Francesco Mureddu, Luigi Tarantini, Mario Velussi, Marco Comaschi.   

Abstract

BACKGROUND: Individuals with diabetes mellitus (DM) have a higher risk to develop heart failure. Clinical guidelines emphasize the importance of early diagnosis of left ventricular dysfunction (LVD) and preventive interventions in these patients. In this study we assessed the prevalence of LVD, systolic or diastolic, in DM patients without known cardiac disease recruited in the 'left ventricular DYsfunction in DiAbetes (DYDA)' study. DESIGN AND METHODS: We performed clinical, ECG, laboratory, and echocardiographic exams in 960 patients (61 ± 8 years, 59% hypertensive) recruited in the DYDA study from 37 Italian diabetes referral centres. ECG and echo exams were read in central facilities. Systolic LVD was defined as ejection fraction ≤ 50% or midwall shortening (MFS) ≤ 15%. Diastolic LVD was identified when transmitral E/A was out of the range of 0.75-1.5 or deceleration time of mitral E wave ≤ 140 msec.
RESULTS: Echocardiographic data were obtained in 751 patients (78.2%). Isolated systolic LVD was detected in 22.0% of patients, isolated diastolic LVD in 21.5%, and combined systolic and diastolic LVD in 12.7%. All patients with systolic LVD had MFS ≤ 15%, while only 9% had an ejection fraction ≤ 50%. Higher LV mass, relative wall thickness, prevalence of concentric geometry, and LV hypertrophy characterized the patients with LVD.
CONCLUSIONS: LVD is present in more than half of DM patients without clinically detectable cardiac disease and is associated with LV hypertrophy and concentric LV geometry. One-third of patients exhibits systolic LVD detectable at the midwall level.

Entities:  

Mesh:

Year:  2011        PMID: 21798988     DOI: 10.1177/1741826711417759

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  9 in total

1.  Combined circumferential and longitudinal left ventricular systolic dysfunction in patients with type 2 diabetes mellitus without myocardial ischemia.

Authors:  Giovanni Cioffi; Giorgio Faganello; Stefania De Feo; Nicola Berlinghieri; Luigi Tarantini; Andrea Di Lenarda; Bruno Pinamonti; Riccardo Candido; Pompilio Faggiano
Journal:  Exp Clin Cardiol       Date:  2013

2.  Nigella sativa: A potential natural protective agent against cardiac dysfunction in patients with type 2 diabetes mellitus.

Authors:  Abdullah Bamosa; Huda Kaatabi; Ahmed Badar; Akram Al-Khadra; Abdulmohsen Al Elq; Bodour Abou-Hozaifa; Fatma Lebda; Sameeh Al-Almaie
Journal:  J Family Community Med       Date:  2015 May-Aug

3.  Prevalence of left ventricular systolic dysfunction and heart failure with reduced ejection fraction in men and women with type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors:  Selma Bouthoorn; Aisha Gohar; Gideon Valstar; Hester M den Ruijter; J B Reitsma; Arno W Hoes; Frans H Rutten
Journal:  Cardiovasc Diabetol       Date:  2018-04-18       Impact factor: 9.951

4.  Neutrophil: lymphocyte ratio is positively associated with subclinical diabetic cardiomyopathy.

Authors:  Xiaoli Huang; Zihan Qin; Min Xu; Feifei Zhang; Xiaohong Jiang; Fei Hua; Lichan Tao
Journal:  BMC Endocr Disord       Date:  2020-06-30       Impact factor: 2.763

5.  Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial.

Authors:  Lorenzo Nesti; Nicola Riccardo Pugliese; Paolo Sciuto; Domenico Trico; Angela Dardano; Simona Baldi; Silvia Pinnola; Iacopo Fabiani; Vitantonio Di Bello; Andrea Natali
Journal:  Cardiovasc Diabetol       Date:  2022-09-12       Impact factor: 8.949

6.  Cardiovascular biomarkers, cardiac dysfunction, and outcomes in patients with type 2 diabetes: a prospective, multicenter study.

Authors:  Serge Masson; Roberto Latini; Giovanni Cioffi; Renato Urso; Tarcisio Vago; Donata Lucci; Gian Francesco Mureddu; Luigi Tarantini; Pompilio Faggiano; Daniela Girfoglio; Mario Velussi; Aldo P Maggioni; Carlo B Giorda; Marco Comaschi
Journal:  Diabetes Care       Date:  2013-09       Impact factor: 19.112

7.  Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial.

Authors:  Andrea Natali; Lorenzo Nesti; Iacopo Fabiani; Enrico Calogero; Vitantonio Di Bello
Journal:  Cardiovasc Diabetol       Date:  2017-10-12       Impact factor: 9.951

8.  The prevalence of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in men and women with type 2 diabetes: A systematic review and meta-analysis.

Authors:  Selma Bouthoorn; Gideon B Valstar; Aisha Gohar; Hester M den Ruijter; Hans B Reitsma; Arno W Hoes; Frans H Rutten
Journal:  Diab Vasc Dis Res       Date:  2018-07-24       Impact factor: 3.291

9.  INtegration of care for reaching targetS In Diabetic patiEnts: Design of the INSIDE Study.

Authors:  Marco Comaschi; Andrea Di Lenarda; Gerardo Medea; Alberto Aglialoro; Domenico Cucinotta; Michele Gulizia; Giacomo Vespasiani; Guerrino Zuin; Antonio Nicolucci; Federico Spandonaro; Aldo Pietro Maggioni
Journal:  Diabetes Ther       Date:  2019-11-22       Impact factor: 2.945

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.